

CLAIM LISTING

1. (Previously Presented) A clonal myeloma cell line capable of:  
growing continuously in a chemically defined medium;  
growing to high cell density in a chemically defined medium;  
remaining viable after cryopreservation in the absence of  
serum; and  
detectably expressing recombinant protein following genetic  
manipulation and culture in a chemically defined medium.
2. (Previously Presented) The cell line of claim 1 derived from  
Sp<sub>2/0</sub> myeloma cells.
3. (Previously Presented) The cell line of claim 2 wherein the  
cell line is C463A cells.
4. (Previously Presented) The cell line of claim 1 derived from  
Ag653 myeloma cells.
5. (Previously Presented) The cell line of claim 4 wherein the  
cell line is C504A cells.
6. (Previously Presented) The cell line of claim 1 wherein the  
genetic manipulation comprises introducing a nucleic acid  
encoding at least one protein into the cell line by  
electroporation, lipofection, calcium phosphate precipitation,  
polyethylene glycol precipitation, sonication, transfection,  
transduction, transformation or viral infection.
7. (Previously Presented) The cell line of claim 1 wherein the  
protein is selected from one or more of the group consisting of  
an immunoglobulin, a cytokine, an integrin, an antigen, a growth  
factor, a cell cycle protein, a hormone, a neurotransmitter, a  
receptor or fusion protein thereof, a blood protein, an

antimicrobial, any fragment thereof, and any structural or functional analog thereof.

8. (Previously Presented) The cell line of claim 5 wherein the immunoglobulin or fragment is selected from one or more of the group consisting of rodent, primate, chimeric, and engineered.
9. (Previously Presented) The cell line of claim 6 wherein the immunoglobulin or fragment is selected from one or more of the group consisting of murine, human, chimeric, humanized, CDR-grafted, phage displayed, transgenic mouse-produced, optimized, mutagenized, randomized, and recombined.
10. (Previously Presented) The cell line of claim 7 wherein the immunoglobulin or fragment is selected from one or more of the group consisting of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, sIgA, IgD, IgE, and any structural or functional analog thereof.
11. (Previously Presented) The cell line of claim 7 wherein said fragment is selected from one or more of the group consisting of  $F(ab')_2$ , Fab', Fab, Fc, Facb, pFc', Fd, Fv, and any structural or functional analog thereof.
12. (Previously Presented) The cell line of claim 1 wherein the protein is produced at about 0.01 mg/L to about 10,000 mg/L of culture medium of said cell line.
13. (Previously Presented) The cell line of claim 1 wherein said protein is produced at a level of about 0.1 pg/cell/day to about 100 ng/cell/day.
14. (Previously Presented) A method for producing at least one protein from a cultured cell comprising the steps of:

culturing cells of the cell line of claim 1 in a chemically defined medium, wherein the cells express said at least one desired protein; and

isolating said at least one desired protein from the chemically defined medium or the cells.

15. (Withdrawn) An isolated protein obtained from cells according to the method of claim 12.

16. (Withdrawn) A method for identifying cell lines capable of growing continuously in a chemically defined medium comprising the steps of:

culturing cells from one type of cell line in at least one type of chemically defined medium, wherein the cultured cells from one type of cell line are not known to grow in the chemically defined medium; and

selecting spontaneous mutant cells that are capable of growing in the chemically defined medium.

17. (Previously Presented) A cell line obtained according to the method of claim 14.

18. (Withdrawn) A protein obtained from the cell line of claim 1.

19. (Previously Presented) The cell line of claim 5 wherein said immunoglobulin is infliximab.

20. (Previously Presented) The cell line of claim 5 wherein said immunoglobulin is rTNV148B.

21. (Previously Presented) The cell line of claim 5 wherein said fragment is abciximab.